Cost-effectiveness of ten commonly used antipsychotics in first-episode schizophrenia in the UK: economic evaluation based on a de novo discrete event simulation model.
Zhou J. et al, (2024), Br J Psychiatry, 1 - 8
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study.
Mihaylova B. et al, (2024), Lancet Reg Health Eur, 40
Medication adherence and costs of medical care among patients with Parkinson's disease: an observational study using electronic medical records.
Yi Z. et al, (2024), BMC Public Health, 24
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Wu R. et al, (2024), Br J Gen Pract, 74, e189 - e198
Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial.
Zhou J. et al, (2023), Pharmacoeconomics
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.
Zhou J. et al, (2023), Pharmacoeconomics, 41, 547 - 559
A systematic review of the factors associated with suicide attempts among sexual-minority youth
Wang XX. et al, (2023), The European Journal of Psychiatry, 37, 72 - 83
Cost-effectiveness of endovascular thrombectomy with alteplase versus endovascular thrombectomy alone for acute ischemic stroke secondary to large vessel occlusion.
Ye Z. et al, (2023), CMAJ Open, 11, E443 - E450
Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis.
Wang K. et al, (2023), Front Aging Neurosci, 15
CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA
Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16
Cost-effectiveness of statin therapy in categories of patients in the UK
Mihaylova B. et al, (2022), EUROPEAN HEART JOURNAL, 43, 2841 - 2841
EXCESS ANNUAL HOSPITAL COSTS DUE TO CARDIOVASCULAR EVENTS IN A CONTEMPORARY UK POPULATION TO INFORM HEALTH TECHNOLOGY ASSESSMENTS
Zhou J. et al, (2022), VALUE IN HEALTH, 25, S12 - S12
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database
Guo M. et al, (2021), International Journal of Clinical Pharmacy, 43, 1508 - 1515
A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts
Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3149 - 3149
Incorporating future unrelated medical costs in cost-effectiveness analysis in China.
Jiang S. et al, (2021), BMJ Glob Health, 6
Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries
Wang Y. et al, (2021), Applied Health Economics and Health Policy, 19, 281 - 304
Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
Clay E. et al, (2019), Journal of Market Access & Health Policy, 7, 1667195 - 1667195
Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
Zhou J. et al, (2019), Journal of Market Access & Health Policy, 7, 1648973 - 1648973